Meet Our 2015 BEBPA Board of Directors and Observers
Dr Bassam Hallis. Bassam has over 25 years experience in scientific research including 15 years in regulated activities including vaccine evaluation, release/stability and clinical trial serology. He has extensive experience in assay development and validation including cell based and functional assays as well as technology transfer of early stage and validated tests.
Public Health England
Salisbury SP4 0JG
Fax: +44 (0)
Dr. Hans-Joachim Wallny is a Technical project leader at the departement „TRD Biologics“, Novartis Pharma AG Switzerland. He was leading the technical team who recently achieved the approval of a monoclonal antibody (ILARIS) for the treatment of a rare autoinflammatory disease (CAPS) in US, EU and Switzerland
Before this assignment he was head of a bioanalytics group, responsible for the development and validation of biological potency assays and high molecular impurity assays for biopharmaceuticals during early development. Prior he was head of the bioassay group, which included the responsibility for routine performance of bioassays for marketed products.
One of his main scientific ambitions was to develop and implement modern, fast and reliable bioassays using early cellular events as read-outs (e.g. reporter gene assays, KIRA assays, etc.). For this he was honored with the title “Novartis Leading Scientist” in 2003.
Prior to joining Novartis in 1997, he was a Lab head in the Biotechnology departement, Research and Development of Biotest Pharma GmbH, Germany, responsible for the development of bioanalytical methods and analytics for preclinical/clinical trials (1995-1997).
Dr. Wallny was previously a Scientist at the Basel Institute for Immunology, Switzerland (1992-1995) after receiving his Ph.D. degree in Biochemistry/Immunology from the University of Tübingen, Germany. Dr. Wallny received a diploma in biochemistry from the University of Tübingen, Germany in 1989.
Novartis Pharma AG
+41 61 324 7383
Dr. Little has been a bioassay consultant for over 20 years. During this time, she worked with small and large pharmaceutical companies in all stages of development as well as supporting authorized products. She has worked with protein products, including antibodies, enzymes, carbohydrate based products, and many other types. Dr. Little also has a vast experience with biopharmaceuticals including vaccines, viruses, cell-based products and combination products. She is the founder of BEBPA and was the original producer of the three largest and most popular bioassay conferences held in Europe and the USA.
P.O. Box 7087
Citrus Heights, CA 95621
Martin Vanderlaan has recently retired after 20 years at Genentech, where he was Director of Analytical Operations. This centralized testing laboratory is unique in the Roche network of sites, and provides analytical testing using such diverse analytical methods as PCR, ICP-MS, HPLC-MS, CE, FTIR, and ELISAs. This laboratory has responsibility for all Genentech process-related impurity testing, such as host cell protein and DNA, and leached Protein A, and all media component testing, such as vitamins, amino acids, and trace metals. Martin’s particular areas of interest include the use of assay automation and robotics, data management in electronic lab notebooks, and host cell protein assays. Martin is a member of the US Pharmacopea Expert Group on host cell protein analysis, a member of the California Separation Science Society, and a member of AAAS and ACS.
Martin has held previous leadership positions at Genentech in departments with responsibility for protein analytical chemistry method development, potency testing, and protein PK assay development. Prior to coming to Genentech, Martin was Director of Immunochemistry at PerSeptive Biosystems, a start-up instrument company in the Boston area. In this capacity, he developed products using immunoaffinity HPLC, and describes himself as being “bilingual”, speaking both the jargons of chromatography and immunoassays and always looking for opportunities for synergism between these techniques. Prior to this, Martin ran one of the first hybridoma laboratories on the West Coast, at Lawrence Livermore National Laboratory. His mAbs for glycophorin blood typing (M/N blood groups) were the industry standard.
Academically, Martin has a BS in physics from the University of California at Santa Barbara, and a Ph.D. from New York University’s Institute of Environmental Medicine, where he specialized in Oncology. More recently, Martin completed an executive MBA at the University of San Francisco. Martin has more than 75 publications, 10 patents, and was editor of the ACS Symposium Series book Immunoassays for Trace Chemical Analysis: Monitoring Toxic Chemicals in Humans, Food, and the Environment.
Board Member Emeritus
Stanley N. Deming, Ph.D. is president of Statistical Designs, Houston, TX, through which he consults and offers short courses in the areas of experimental design, optimization, and the statistical analysis of laboratory data, with emphasis on bioassays. Dr. Deming received his B.A. degree in chemistry from Carleton College, Northfield, MN, and his M.S. and Ph.D. degrees in analytical chemistry from Purdue University, West Lafayette, IN. He has been on the chemistry department faculties of Emory University (1970-1974) and the University of Houston (1974-2001) where he is Professor Emeritus. Over his academic career he was the major research advisor for 16 Ph.D. students and 19 M.S. students. Since 1975 he has taught (with Stephen L. Morgan) over 600 short courses.
Dr. Deming has been the author or co-author of approximately 100 papers and three books, including Experimental Design: A Chemometric Approach (Elsevier) and Sequential Simplex Optimization: A Technique for Improving Quality and Productivity in Research, Development, and Manufacturing (CRC Press). He has served on the editorial boards of the Journal of Chemometrics (1987-2003), Critical Reviews in Analytical Chemistry (1996-2002), and Chemometrics and Intelligent Laboratory Systems (1987-1993). His web site is http://www.statisticaldesigns.com.
8423 Garden Parks Dr.
Houston, TX 77075
tel: 281 841 3992
Dr. C. Jane Robinson is a consultant in biopharmaceutical development, specializing in in-vitro bioassays and reference standards. Previously, she worked for 25 years at the National Institute for Biological Standards and Control (NIBSC), UK, where she established a laboratory for the testing and standardization of polypeptide growth factors of therapeutic and diagnostic potential. Dr. Robinson has advised regulatory authorities and other organizations on bioassay design and analysis, led collaborative projects to develop World Health Organization international standards and participated in the European Directorate for the Quality of Medicines and Healthcare (EDQM) testing of Centrally Approved Products. Dr. Robinson has lectured and provided training for regulatory, professional, academic and commercial organizations. She received her Ph.D. degree in chemistry from the Katholieke Universiteit te Leuven, Belgium in 1982.
Cori Schrader attended UC Davis and graduated in 2004 with a Bachelor of Arts degree for Political Science and Pre-Industrial European History. Since graduation, Cori has worked with BioQuality Newsletter as an editor. In 2008 Cori became the meeting organizer for BEBPA.
P.O. Box 7087
Citrus Heights, CA 95621
tel: 916 729 0109
fax: 916 729 0134